NCT06487767

Brief Summary

The study wil aim to investigate the accuracy of imaging in the staging of women diagnosed with cervical cancer

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jul 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Jul 2024Dec 2026

First Submitted

Initial submission to the registry

June 27, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 5, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

July 5, 2024

Status Verified

June 1, 2024

Enrollment Period

2 years

First QC Date

June 27, 2024

Last Update Submit

June 27, 2024

Conditions

Cervical Cancer Stage, Imaging Modalities

Keywords

Cervical cancerUltrasoundMRICT ScanPET-CT scan

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity

    Metrics of imaging

    2 years

Interventions

SurgeryOTHER

Surgery for operable cervical cancer

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen diagnosed with cervical cancer
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Women diagnosed with cervical cancer scheduled for surgical treatment or intervention

You may qualify if:

  • \- Women diagnosed with cervical cancer Able and willing to provide informed consent

You may not qualify if:

  • Previously treated for cervical cancer Unable to provide informed consent Patients with contra-indications to undergo surgical treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kalafong Provincial Tertiary Hospital

Pretoria, Gauteng, South Africa

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Cathy Visser, MSc

    Trial administrator

    STUDY DIRECTOR

Central Study Contacts

Edwin F Mnisi, MMed (O&G)

CONTACT

+27766129797edwinmnisi@hotmail.com

Leon C Snyman, PhD

CONTACT

+27834621818leon.snyman@up.ac.za

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 27, 2024

First Posted

July 5, 2024

Study Start

July 1, 2024

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

July 5, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations

ZA(1)